Zacks Investment Research on MSN
Here is what to know beyond why CRISPR Therapeutics AG (CRSP) is a trending stock
CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...
How does the first CRISPR treatment work? Can biotech rebound? And when is $300 million not $300 million? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. With the ...
A new CRISPR approach can control genes without cutting DNA, opening a safer path for treating genetic diseases. A newly ...
“It’s a little scary, quite honestly,” says Dr. Jennifer Doudna, who helped develop CRISPR gene-editing technology. By David Marchese It’s entirely possible, maybe even likely, that during some slow ...
In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...
Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins are core components of fast-evolving therapeutic gene editing tools. Scientists have used CRISPR ...
A dire wolf de-extinction debate, CRISPR-GPT for gene editing, and more topped the list of our most popular stories in ...
Morning Overview on MSN
CRISPR researchers revived an ancient gene that could block disease
Researchers have used CRISPR to switch back on a gene that vanished from the human lineage roughly 20 million years ago, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results